The Hidden Struggle Study is LIVE. We’re uncovering the global mental health burden among oncology physicians — beyond burnout, to depression, anxiety, and the support gaps no one talks about. DM or email [email protected] to join. #Oncology #MentalHealth

Calling all young oncologists across LATAM! 🌎 Share your experiences and insights in this regional survey on the needs and challenges of young oncologists in Latin America. 🗳️ Take the survey 👉 docs.google.com/forms/d/e/1FAI… #Oncología #LATAMOncology

This is for young oncologists across LATAM! 🌎 Share your experiences and insights in this regional survey on the needs and challenges of young oncologists in Latin America. 🗳️ Take the survey 👉 docs.google.com/forms/d/e/1FAI… #Oncología #LATAMOncology

The #OncoalertTopTweet DAY One #ESMO25 🚨THE NEWSLETTER IS OUT REGISTER HERE👉 buff.ly/RkOToac #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO

The #OncoalertTopTweet DAY One #ESMO25 🚨THE ONCOALERT INITIATIVES IN BERLIN for ESMO 2025 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD Dr Joseph McCollom DO Erman Akkus

We are in Berlin for #ESMO25 The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 . We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.

The #OncoAlertTopTweet 🚨 Day THREE #ESMO25 Post from OncoAlert 🌐 Day 3 154 Million Impressions Stats from MedTrackSocial.com Dra. María Natalia Gandur Quiroga Hidehito HORINOUCHI Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Erman Akkus Luca Arecco, MD Gaia Griguolo Kristina Jankovic, MD Mario Balsa

The OncoAlert🚨Round Up Day THREE of #ESMO25 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: OUR TOP 5⃣ PICKS Presented Oct 19, 2025 ✅HARMONi-6 (Lancet) ✅OptiTROP-Lung04 (NEJM) ✅PSMAddition ✅Disitamab vedotin (DV) plus toripalimab (NEJM)

Important update in Nature Reviews Cancer #dMMR cancers have unique #ICI sensitivity. Universal testing is key; #ICI show broad efficacy, but predictive biomarkers 🎯and responses vary by #tumor type. 🔗: nature.com/articles/s4157… OncoAlert🚨 #OncoAlertAF Fadi Haddad, MD

As we get closer to the end of #ESMO25 🇩🇪 Huge thanks to ESMO and our colleagues for their Support! WE ARE ALL OncoALert 🚨 See you in Madrid #ESMO26 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Hidehito HORINOUCHI Fadi Haddad, MD Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto

KEYNOTE 905 Out on #ESMO25 #BladderCancer Study Breakdown the first perioperative study in cisplatin-ineligible muscle-invasive bladder cancerto show survival benefit. Enfortumab vedotin plus pembrolizumab improved event-free survival, overall survival, and pathologic complete

DESTINY Breast 05 presented at #ESMO25 Study breakdown T-DXd-THP in high-risk HER2+ 🧬early #BreastCancer Results mirrored Breast11 — a pCR rate of 67% vs 56% and a favorable safety profile with less grade ≥3 toxicity and less cardiotoxicity. Matteo Lambertini, MD PhD Philippe Aftimos, MD 

ASCENT 03 presented at #ESMO25 Study breakdown In #TNBC #BreastCancer , the ASCENT-03 trial assessed sacituzumab govitecan in previously untreated patients ineligible for PD-1 or PD-L1 inhibitors. The ADC improved progression-free survival from 6.9 to 9.7 months, with more

Dear Colleagues at #ESMO25 Oncology: Here & Now is BACK ‼️ S2E1 GU Oncology Here they discuss Lutetium PSMA or Deferred ADT Listen Here: youtu.be/FSrJ5iL3F-c?si… Join Bárbara Melão, MD, PhD 🇧🇷& Danny Mena - nuclear medicine 🇲🇽 on this Great Webcast as they discuss #ProstateCancer : ✅Rationale between

AMAZING Numbers for day 4 of #ESMO25 🇩🇪 2⃣0⃣4⃣ Million impressions 1⃣2⃣.8⃣K Posts KUDOS ESMO!!! 👉Stats Powered by MedTrackSocial.com OncoAlert 🚨 Gil Morgan, MD Matteo Lambertini, MD PhD Toni Choueiri, MD Dra. María Natalia Gandur Quiroga Hidehito HORINOUCHI Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD

Mi querida Regina Barragan-Carrillo y Dra. María Natalia Gandur Quiroga rompiéndola en su nuevo podcast!! 🚨 OncoAlert

The OncoAlert🚨Round Up Day FOUR of #ESMO25 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: OUR TOP 5⃣ PICKS Presented Oct 19, 2025 ✅IMvigor011 ✅DYNAMIC III ✅FORTITUDE 101 Tom Powles Alfonso Gómez de Liaño Nirmal Raut Rana McKay, MD, FASCO Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

On behalf of the Network, We would like to thank OUR #OncoAlertAF 🚨 for their amazing coverage of #ESMO25 🇩🇪 WE ARE #OncoAlertAF ‼️ 🇺🇸 @WeOncologists 🇧🇪 Elisa Agostinetto 🇦🇷 Dra. María Natalia Gandur Quiroga 🇮🇹 Elisabetta Bonzano MD, PhD 🇯🇵 Hidehito HORINOUCHI 🇪🇸 Mario Balsa 🇪🇸 Oriol Mirallas MD 🇺🇸

First #ESMO ✅ 35k attendees, countless insights and new hopes for patients. Proud to present + receive a Merit Award.Huge thanks to Prof. Yüksel Ürün , Ankara Univ. Oncology, TTOD & my colleagues—mentors and friends Ioanna Nixon Vilma P. Barcia ESMO - Eur. Oncology ESOncology OncoDaily

Top GI Cancer Oncologists from ESMO - Eur. Oncology 2025 Explore more insights and data from #ESMO25: t.ly/yDvnj #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #GICancer | Erman Akkus | Arndt Vogel | Nicholas Hornstein |